The 12-week treatment protocol enrolled a total of 433 subjects across 61 clinical sites in the US and Korea. The study is a joint development program between Melior Pharmaceuticals I and its Asian development partner, Bukwang Pharmaceutical Company (Korea).
This study follows a positive Phase 2a proof-of-concept study that the partners completed last year in which statistically significant glucose lowering was achieved for both glucose parameters (fasting plasma glucose and area-under-the curve in a mixed meal tolerance test).
In addition, positive trends were seen in lipid parameters and body weight in that four-week study.
Tolimidone (MLR-1023) is a first-in-class Lyn kinase activator that serves as a dual non-PPAR insulin sensitizer and modulator of lipid metabolism which is in development for the treatment of Type 2 diabetes.
In addition to the positive effect on glucose, lipids and weight observed in the recent clinical POC study, improvement of in beta cell function has been characterised in animal models of diabetes.
Increasing understanding for the role of Lyn kinase activation has led Melior to explore development of tolimidone in other disease areas with significant unmet needs.
Nonalcoholic steatohepatitis is the most advanced of these programmes. Melior expects to initiate clinical development in NASH in early 2019.
Melior has partnered with Bukwang Pharmaceutical company for the rights to develop and commercialise in Type 2 diabetes in the Asia region, excluding Japan, and is currently exploring global partnering opportunities with other parties in the US, EU, and Japan.
Melior Pharmaceuticals is developing a pipeline of de-risked therapies in areas with significant unmet needs, including diabetes, NASH, Parkinson's disease and sleep disorders.
The company leverages the proprietary drug-repositioning technology of its affiliate company, Melior Discovery, to identify new targets and indications for drug candidates that have already undergone clinical studies in other indications. Melior Pharmaceuticals and Melior Discovery are privately held and located in Exton, PA.
Bukwang Pharm. Co., Ltd. is a leading Korean pharmaceutical company listed on the Korean Stock Exchange [KRX:003000].
The company has been in business for over 50 years.
Sales are primarily derived from products licensed from Europe, the United States and Japan. The company is currently investing significant resources in R and D to create a robust pipeline of preclinical and clinical agents for the treatment of oncology, gastrointestinal disorders, CNS disorders and metabolic diseases.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults